CV-MG01: A new hope in research for dogs with myasthenia gravis and megaesophagus

At Mega-Dog, we closely follow any developments that can improve the lives of dogs with megaesophagus and their families. And in recent weeks, a particularly interesting development has occurred in Europe.

Belgian biotech company CuraVac is making progress in the development of CV-MG01 , an experimental therapy aimed at treating canine myasthenia gravis.

Why are we talking about it on Mega-Dog?

Because myasthenia gravis is one of the diseases that can cause acquired megaesophagus in dogs . In these animals, the disruption of neuromuscular transmission can also affect the esophagus, hindering the transport of food to the stomach. Megaesophagus is, in fact, a common manifestation of canine myasthenia gravis.

What is CV-MG01?

CV-MG01 is an experimental immunotherapy developed by CuraVac using a technology that the company calls Targeted Active Therapy .

Acquired myasthenia gravis is an autoimmune disease in which certain antibodies interfere with the acetylcholine receptors needed to properly transmit signals between nerves and muscles.

CuraVac's strategy seeks to act specifically against the autoantibodies involved in the disease, instead of performing a generalized immunosuppression.

This is a particularly interesting approach, but it is important to emphasize something:

CV-MG01 remains an experimental treatment and is not yet commercially available.

Two dogs treated through compassionate use

One of the first cases reported by CuraVac was that of Uto , a Golden Retriever diagnosed with myasthenia gravis when he was nine months old.

According to data published by the company, Uto received three doses of CV-MG01 through compassionate use and achieved complete remission approximately six weeks later. CuraVac reported in January 2026 that the dog remained symptom-free more than two years after treatment.

A second case came to light in July 2026.

Teddy , a five-year-old Labradoodle diagnosed with myasthenia gravis, also received CV-MG01 through compassionate use, in collaboration with Ludwig Maximilian University of Munich. CuraVac reported a favorable outcome in the weeks following treatment.

These results are encouraging, but they should be interpreted with caution: individual cases treated through compassionate use do not yet demonstrate the efficacy and safety of a drug in a large population of dogs .

That regulatory process continues.

The next step: obtaining veterinary authorization

CuraVac announced in July 2026 the creation of its veterinary unit with the stated goal of being able to market a treatment for canine myasthenia gravis in 2028 .

The company also notes that CV-MG01 has progressed within the European framework for veterinary medicines intended for limited markets , a category specifically designed to facilitate the development of treatments for rare animal diseases. European regulations provide a specific authorization pathway for this type of medicine.

On October 5, 2026, CuraVac also announced a new funding round to complete the final development steps of CV-MG01 before submitting its application for market entry. The company states that the scientific advice received in 2026 allows it to move forward with a future application for marketing authorization.

Therefore, this is an important advance, but not a drug that can currently be prescribed by a veterinarian .

What does all this have to do with megaesophagus?

This is probably the most interesting part for our community.

Megaesophagus is not a single disease. It is a condition in which the esophagus loses some of its ability to properly transport food and liquids to the stomach.

It can be congenital, idiopathic, or appear as a consequence of other diseases.

Among those causes is precisely myasthenia gravis .

When an identifiable underlying disease exists, treating that cause is an essential part of veterinary management.

Therefore, if CV-MG01 successfully completes its development and obtains the corresponding authorization in the future, it could represent a new therapeutic alternative for certain dogs whose megaesophagus is associated with myasthenia gravis .

And that nuance is fundamental:

It would not be a treatment for all dogs with megaesophagus.

Meanwhile, daily driving remains essential

Regardless of pharmacological advances, dogs with megaesophagus require home management adapted to their situation and always supervised by their veterinarian.

Feeding in an elevated or upright position, and maintaining that position after eating, uses gravity to help food move down to the stomach. The texture of the food, the number of meals, and the time needed after each feeding can vary from dog to dog.

That is precisely the space in which we work at Mega-Dog .

Our Bailey Chair is designed to make daily handling at home easier, and our goal is to support families through a process that may initially seem complex.

We do not diagnose.

We do not replace the veterinarian.

And a Bailey chair does not treat the disease that causes megaesophagus.

It is a support tool to facilitate feeding and home routines indicated for these dogs .

Veterinary treatment and home care must go hand in hand.

News like that of CuraVac seems especially relevant to us because it shows where the treatment of rare diseases in veterinary medicine can evolve.

Perhaps in the coming years we will have access to treatments that are increasingly targeted at some of the causes of megaesophagus.

That would be excellent news.

But even then, there will still be a period between diagnosis, treatment, and recovery during which many families will need to learn how to feed their dog, record its progress, identify changes, and maintain close communication with their veterinarian.

At Mega-Dog we believe that the future lies precisely in connecting those two worlds:

veterinary treatment and daily home care.

We will closely follow the evolution of CV-MG01 and the CuraVac research.

Because every advance that allows us to better understand the disease, treat its cause, or improve the quality of life of these dogs is also good news for the entire megaesophagus community.

Important note: CV-MG01 is currently an experimental treatment under development and is not authorized for commercialization. The information in this article is for informational purposes only and does not constitute veterinary advice. Any suspected megaesophagus or myasthenia gravis should be diagnosed and treated by a veterinary professional.